2 hours ago
1
JHVEPhoto
Drug developers with products targeting a liver condition called metabolic dysfunction-associated steatohepatitis (MASH) traded higher on Wednesday after the U.S. FDA said it has accepted an easy-to-measure biomarker as a surrogate endpoint to measure hepatic function in clinical trials.
In
English (US) ·